Subsynaptic positioning of AMPARs by LRRTM2 controls synaptic strength

Austin M. Ramsey1,2†, Ai-Hui Tang1††, Tara A. LeGates1,2§, Xu-Zhuo Gou‡, Beatrice E. Carbone4||, Scott M. Thompson1,2,3, Thomas Biederer4, Thomas A. Blanpied1,2*

Recent evidence suggests that nano-organization of proteins within synapses may control the strength of communication between neurons in the brain. The unique subsynaptic distribution of glutamate receptors, which cluster in nanoclusters with presynaptic sites of glutamate release, supports this hypothesis. However, testing it has been difficult because mechanisms controlling subsynaptic organization remain unknown. Reasoning that transcellular interactions could position AMPA receptors (AMPARs), we targeted a key transsynaptic adhesion molecule implicated in controlling AMPAR number, LRRTM2, using engineered, rapid proteolysis. Severing the LRRTM2 extracellular domain led quickly to nanoscale declustering of AMPARs away from release sites, not prompting their escape from synapses until much later. This rapid remodeling of AMPAR position produced significant deficits in evoked, but not spontaneous, postsynaptic receptor activation. These results dissociate receptor numbers from their nanopositioning in determination of synaptic function and support the novel concept that adhesion molecules acutely position receptors to dynamically control synaptic strength.

INTRODUCTION

The complex neural processes of information encoding, storage, and retrieval are enabled by fine regulation of synaptic strength. It is well established that the number of AMPA-type glutamate receptors (AMPArs) within a single synapse is a key property determining the amplitude of the excitatory postsynaptic current (EPSC) response to neurotransmitter release (1–3). However, several constraints appear to limit AMPAR activation following glutamate release (4–6), suggesting that factors beyond receptor number also control synapse strength. Among the most critical is that a variety of modeling approaches suggest that AMPARs even at ~90 nm from the site of glutamate release open with only about half the likelihood of those close to the site of vesicle fusion (7, 8) due to the low affinity and rapid desensitization of receptors (9–11). This greatly diminishes the expected EPSC, a prediction in line with experimental results suggesting that glutamate release from a single vesicle is not sufficient to maximize postsynaptic receptor activation (12, 13). Unfortunately, it has been difficult to test whether such distance dependence plays a physiological role in neurons because the mechanisms that determine the precise positioning of receptors across sites of release are not known.

Discerning these mechanisms is complex because AMPARs and a number of scaffolding molecules involved in their synaptic retention, most notably postsynaptic density 95 (PSD-95), are nonhomogeneously distributed within individual PSDs, forming nanometer-scale clusters (14–17). Similarly, within the presynaptic active zone (AZ), molecules critical for vesicle priming and Ca2+ channel recruitment such as the Rab3 interacting molecule (RIM) and Munc13 are clustered into ~100-nm nanodomains (18). These active zone nanodomains are widely conserved across many synapse types (19) and are thought to govern vesicle positioning and establish sites in the active zone where action potentials drive synaptic vesicle exocytosis with highest probability (20, 21). Critically, in mammalian brain, presynaptic sites of glutamate exocytosis as marked by RIM nanoclusters are aligned with postsynaptic nanoclusters of AMPARs across the cleft in an organization referred to as a nanocolumn (20, 22, 23). If receptor distance to the site of neurotransmitter exocytosis regulates receptor activation, then this aligned organization likely enhances basal excitatory synaptic transmission, and its disruption would reduce synaptic strength. This is important to determine since modulation of transsynaptic alignment then would open a number of different mechanisms of synaptic plasticity (24).

It remains unclear how subsynaptic alignment of receptor clusters with release sites is created or maintained. Although many models have been proposed (5), perhaps the most parsimonious idea is that cleft-resident synaptotagmin molecules (CAMs) link pre- and postsynaptic nanodomains through their transsynaptic binding interactions. The most prominent candidates to test for this role are the neuroligin (NL) and leucine-rich repeat transmembrane (LRRTM) families that are postsynaptic partners of presynaptic neurexins and that bind PSD-95 (25). However, such tests are complicated because CAM families are large, the roles they play are diverse, and the family members exhibit substantial redundancy upon knockout (26, 27). Disruption of postsynaptic NL by expression of dominant negative mutants or prolonged incubation with interfering peptides does alter receptor alignment with RIM (28), providing support for the idea. However, these extended treatments also prompt a complex set of other effects including altering synapse numbers, postsynaptic vesicle release probability, and frequency of spontaneous transmission (28–31).
Proteins in the LRRTM family are strong candidates to mediate transsynaptic alignment. A key abundant family member in hippocampus, LRRTM2, binds postsynaptic PSD-95 through a C-terminal motif (32, 33) and the presynaptic neurexin-hepan sulfate complex through 10 extracellular LRR repeats (34). LRRTM2 has been found to be important for evoked AMPAR-mediated, although not NMDA receptor (NMDAR)–mediated, synaptic transmission independent of synaptogenesis (35). Furthermore, the extracellular domain (ECD) of LRRTM2 alone is sufficient to rescue AMPAR-mediated synaptic transmission following LRRTM1 and LRRTM2 double knockout, a mechanism proposed to be achieved by the anchoring of AMPARs in the PSD (35, 36). LRRTM2 within synapses also forms nanocluster scales of similar size to scaffold, receptor, and release machinery nanodomains (37). Thus, we hypothesized that LRRTM2 coordinates positioning of receptors relative to evoked release sites.

Long-term manipulations can prompt substantial reorganization of synapses that makes deducing the native state difficult. To test the role of LRRTM2 while avoiding such effects, we used acute extracellular proteolysis of an engineered cleavage site to disrupt its extracellular interactions within seconds, thus uncoupling it from the postsynaptic membrane while avoiding complications of genetic compensation. With this approach, we found that LRRTM2 acutely controls the fine positioning of AMPARs relative to the site of release. The repositioning of AMPARs following loss of the LRRTM2 ECD leads to reduction in the amplitude of evoked but not spontaneous responses. Further, the basal distribution of LRRTM2 is in nanoscale register with both RIM and AMPAR nanodomains. Together, these data suggest that postsynaptic LRRTM2 establishes a transcellular, structural linkage mediating nanocluster alignment of AMPARs with preferential sites of evoked neurotransmitter release and provide strong evidence that AMPAR organization within the synapse is critical for the strength of basal synaptic transmission.

RESULTS

Acute and specific cleavage of the LRRTM2 ECD

To test the role of LRRTM2 extracellular interactions in synapse structure and function independent of synaptogenesis and genetic compensation, we adapted a previous approach (38) and inserted the short recognition sequence for the endoprotease thrombin (LVPRGS) at an extracellular, juxtamembrane position within human LRRTM2 (Fig. 1A). To visualize the molecule and enable live-cell measurement of its cleavage in neurons, we appended enhanced green fluorescent protein (EGFP) to the N terminus and used this to replace endogenous LRRTM2 following knockdown with published short hairpin RNA (shRNA) targeting sequences. We denote the molecule GFP-Thr-LRRTM2*, where * indicates the human sequence designed to be resistant to the shRNA (33, 39).

These modifications of LRRTM2 did not appear to disrupt its function. When expressed in cultured rat hippocampal neurons, GFP-Thr-LRRTM2* clustered avidly in small puncta that colocalized nearly exclusively with synapses immunolabeled for PSD-95 and RIM1/2 (Fig. 1, B and C), although some puncta appeared in the dendritic shaft apart from synapses. In addition, when expressed in human embryonic kidney (HEK) cells, GFP-Thr-LRRTM2* trafficked strongly to the plasma membrane and retained the synaptogenic ability of wild-type LRRTM2 to cluster presynaptic markers in the axons of cocultured wild-type neurons (Fig. 1D and fig. S1A).

Although knockdown of LRRTM2 was successful (fig. S2), typical rescue strategies can still result in overexpression. Since overexpression of LRRTM2 in cultured neurons increases excitatory synapse density (33, 39), we tested for functional effects of LRRTM2 overexpression by measuring synapse density via PSD-95 immunolabeling. As expected, expression of GFP-Thr-LRRTM2* without concurrent knockdown resulted in a ~1.3-fold increase in PSD-95 puncta compared to controls expressing cytosolic mCerulean3 alone (Fig. 1E). However, puncta density was unchanged following knockdown of endogenous LRRTM2 and replacement with GFP-Thr-LRRTM2*. Similarly, compared to mCerulean-transfected neurons, spine numbers were increased by GFP-Thr-LRRTM2* overexpression but were unchanged following knockdown and replacement (Fig. 1F). Overexpression also resulted in an increase in spine length, although not in spine area, but we found no changes in either measure with the knockdown replacement approach (Fig. 1, G and H). The replacement strategy also minimized nonsynaptic localization of GFP-Thr-LRRTM2*, which was enriched much more specifically in synapses when endogenous LRRTM2 was knocked down as judged by the levels of thrombin-sensitive extrasynaptic fluorescence (fig. S1B). These data suggest that GFP-Thr-LRRTM2* incorporates readily into excitatory synapses without disrupting synaptogenesis and with minimal effects of overexpression.

Next, we tested whether thrombin successfully cleaved GFP-Thr-LRRTM2* in synapses, particularly at low working concentrations to avoid potential effects that could be mediated via protease-activated receptors (40). Following baseline measurements of EGFP fluorescence, we bath-applied thrombin at 10 U/ml. This prompted the rapid and robust loss of GFP fluorescence from puncta in dendritic spines (Fig. 1, I and J). Thrombin application to neurons expressing GFP-LRRTM2* (with no thrombin recognition sequence) resulted in no decrease in fluorescence, indicating that the loss was due to the cleavage of the ECD and not the nonspecific effects of thrombin (Fig. 1I, top). The LRRTM2 ECD was lost with a time constant of \( \tau = 11.08 \text{ s} \) (95% confidence interval, 10.74 to 11.43 s; Fig. 1I), unexpectedly rapid given its presumed interactions within the synaptic cleft. Incubations in thrombin for up to 1 hour showed sustained loss of GFP-Thr-LRRTM2* (fractional fluorescence remaining: 0.09 ± 0.02 compared to baseline; means ± SEM; Fig. 1K) but no loss of the LRRTM2 ECD in GFP-LRRTM2*–transfected neurons (fraction remaining: 0.96 ± 0.05 compared to baseline; Fig. 1K). The rate of cleavage is likely limited by the speeds of perfusion and proteolysis but, regardless, suggests that LRRTM2 ECD interactions are insufficient to immobilize it for substantial periods within the synaptic cleft. In addition, the quick action and extensive loss of fluorescence confirms that GFP-Thr-LRRTM2* was trafficked to the cell surface, as expected, and suggests that LRRTM2 is only minimally retained intracellularly at steady state in these neurons. Overall, these results demonstrate that expressed GFP-Thr-LRRTM2* localizes appropriately to excitatory synapses, retains its synaptogenic activity, induces no observable morphological changes in spines, and can be proteolytically cleaved acutely and specifically on demand.

No rapid loss of AMPARs following removal of the LRRTM2 ECD

The role of LRRTM2 in synaptogenesis has been well studied, but its functions in established synapses have been explored in far less detail. The four C-terminal amino acids in its intracellular domain form a PDZ-binding motif that is thought to play a role in the
Fig. 1. Acute and specific cleavage of the LRRTM2 extracellular domain. (A) Schematic demonstrating the juxtamembrane insertion of the thrombin recognition sequence (I8) and the N-terminal GFP* denotes co-packaging of an shRNA (I32) that targets endogenous LRRTM2 expressed in the same vector as GFP-Thr-LRRTM2. LNS, laminin/neurexin/sex hormone-binding globulin-domain. (B) Expression of GFP-Thr-LRRTM2* in cultured hippocampal neurons and immunostaining of endogenous PSD-95 and RIM1/2 visualized by confocal microscopy. Scale bars, (left) 30 μm and (right) 10 μm. (C) Quantification of the localization between expressed GFP-Thr-LRRTM2*, RIM1/2, and PSD-95. (n = 120 synapses/6 neurons/2 independent cultures per condition). (D) Quantification of Bassoon recruitment by LRRTM2 in an HEK-neuron coculture synaptogenesis assay alongside positive [cyan fluorescent protein (CFP)–NL-1] and negative (CFP alone) controls. CFP alone (n = 30 cells per two independent cultures), CFP–NL-1 (n = 34/2), BRS-Thr-LRRTM2* (n = 24/2), GFP-Thr-LRRTM2* (n = 25/2), and GFP-LRRTM2* (n = 32/2). (E) Quantification of PSD-95 puncta density in neurons expressing GFP-Thr-LRRTM2* (KDR; n = 19 neurons/3 independent cultures), GFP-Thr-LRRTM2 (OE; n = 16/3), or cytosolic mCerulean3 (Cer3; n = 15/3). (F) Quantification of spine length (n = 10/3). (G) Quantification of spine area (n = 10/3). (I) Representative images from a confocal time series of GFP-Thr-LRRTM2* cleavage following thrombin application (red arrow; 10 U ml−1). Scale bars, 10 μm. (J) Quantification of GFP-Thr-LRRTM2* (n = 100 synapses/5 neurons/3 independent cultures) and GFP-LRRTM2* (n = 40/2/2) cleavage. (K) Quantification of GFP-LRRTM2* (n = 100/5/2) or GFP-Thr-LRRTM2* (n = 120/6/2) for up to 60 min after thrombin exposure. One-way analysis of variance (ANOVA) with post hoc Dunnett’s test was used in (E) to (H). Data are presented as means ± SEM. *P ≤ 0.05 and **P ≤ 0.01.
recruitment of PSD-95 in developing synapses (33), through interactions with the first and second PDZ domains of PSD-95 (32). We considered whether maintenance of PSD-95 at established synapses depends on stable LRRTM2 extracellular interactions. To test this, we cotransfected neurons with GFP-Thr-LRRTM2* and PSD-95*–mCherry (here, * also denotes resistance to coexpressed shRNA) (15) and measured their fluorescence intensity over the course of a 30-min thrombin application. Notably, despite a large and sustained reduction in the GFP-Thr-LRRTM2* fluorescence (fraction remaining: 0.15 ± 0.07; Fig. 2, A to C), PSD-95*-mCherry fluorescence at synapses remained unchanged (fraction remaining: 0.94 ± 0.05; Fig. 2, A to C). Immunocytochemical analysis of synaptic PSD-95 content after thrombin cleavage (discussed below) confirmed this result. Thus, the interactions of LRRTM2 within the synaptic cleft are not necessary for the retention of PSD-95 in established synapses.

LRRTM2 is important for both establishing the number of GluA1-containing synapses and basal synaptic content of GluA1 and GluA2 (33, 36, 41). In neurons at rest, many AMPARs continuously diffuse within the synapse and exchange between synaptic and extrasynaptic domains on a time scale of seconds to minutes (42), but the mechanisms that counteract diffusion and enrich them in the PSD are incompletely understood. Extracellular interactions in the synaptic cleft may be important, and it is conceivable that the ECD interactions of LRRTM2 could assist in the stabilization of both LRRTM2 and, additionally, GluA1-containing AMPARs in established synapses. To visualize synaptic AMPAR content during live imaging before and after cleavage of LRRTM2, we used superecliptic pHluorin (SEP)–tagged GluA1 and GluA2, as previously described (43). We expressed these receptors along with a version of LRRTM2* in which the GFP was replaced with the smaller α-bungarotoxin recognition sequence (BRS) (BRS-Thr-LRRTM2*) (44), which retained its synaptogenic activity (see Fig. 1D and fig. S1) and allowed us to select the wavelength of the labeled α-bungarotoxin. Alexa Fluor 647 (Alexa-647) conjugated to α-bungarotoxin was applied to live cells, resulting in synapse-specific labeling and visualization of the LRRTM2 ECD in cotransfected neurons. We predicted that if the LRRTM2 ECD interacts directly or indirectly with the GluA1 ECD, then its acute loss would reduce SEP-GluA1,2 content in synapses. As with GFP-Thr-LRRTM2*, thrombin application produced a rapid and marked loss of α-bungarotoxin–Alexa-647 fluorescence (fraction remaining: 0.10 ± 0.02; Fig. 2, D to F), indicating cleavage and dispersal of the LRRTM2 ECD. However, SEP-GluA1,2 fluorescence colocalized with LRRTM2 puncta did not decrease even after 10 or 30 min (fraction remaining: 0.96 ± 0.03; Fig. 2, D to F), suggesting no changes in the number of receptors present within the PSD. Furthermore, neurons expressing SEP-GluA1/2 along with the cleavable or noncleavable versions of LRRTM2* showed no difference in the SEP-GluA1,2 synaptic cluster localization density as measured by direct stochastic optical reconstruction microscopy (dSTORM) after a 10-min thrombin treatment (Mann-Whitney test, P = 0.83; data discussed below; fig. S3). These data suggest that the LRRTM2 ECD is not required for the synaptic retention of AMPARs within a time frame of 30 min, during which many receptors exchange in and out of the synapse (45).

This result was unexpected because conditional knockout of LRRTM1 and LRRTM2 leads to a reduction in AMPAR content and EPSC amplitude at established synapses (35). One major difference between the conditional deletion and the acute cleavage is the vastly differing time scales of the two approaches. To test whether the prolonged loss of the LRRTM2 ECD affects AMPAR retention in synapses, we performed live-cell imaging for up to 2 hours after cleavage. Synaptic AMPAR content remained almost completely unchanged for at least 60 min after LRRTM2 cleavage. Only after this, a slow decline sets in, and 2 hours after cleavage, there was a 23.55 ± 0.08% reduction in AMPAR content compared to noncleavable controls (fig. S4). To examine longer time points, we fixed transfected neurons 24 hours after thrombin treatment and stained for surface SEP-GluA1,2. Compared to controls expressing noncleavable BRS-LRRTM2*, neurons that underwent LRRTM2 cleavage displayed much weaker surface SEP-GluA1,2 expression (fig. S4). These data corroborate the previously reported idea that LRRTM2 is important for AMPAR stability in synapses (35) but show that this effect plays out only over extended periods without the LRRTM2 ECD.

Another possible role of LRRTM2 may be to instruct organization of presynaptic release machinery. To test this, we transfected cultured hippocampal neurons with GFP-Thr-LRRTM2* along with soluble mCerulean3 to identify transfected spines following elimination of the EGFP fluorescence after cleavage. Then, following live-cell cleavage of LRRTM2 with thrombin (10 U/ml) for 10 min, cells were fixed, permeabilized, and stained for endogenous PSD-95 and the critical presynaptic scaffolding molecule RIM1/2. Despite near-complete elimination of EGFP fluorescence at transfected spines, we observed no changes in endogenous RIM1/2 content (fraction remaining: 1.06 ± 0.06 compared to vehicle; Fig. 2, G to I). These data suggest that LRRTM2 is not necessary for the retention of RIM in the active zone. Analysis of PSD-95 staining intensity further confirmed that the cleavage of LRRTM2 in established synapses did not change the PSD-95 content (fraction remaining: 1.02 ± 0.06 compared to vehicle; Fig. 2, G to I), supporting our earlier observations during live imaging. Taking these data together, we conclude that, although the LRRTM2 ECD is quickly lost after thrombin cleavage in established synapses, its acute removal does not rapidly lead to loss of other key molecules, including AMPARs.

**LRRTM2 is enriched within the transsynaptic nanocolumn**

Growing evidence indicates that different CAMs have unique and distinct organizations within excitatory synapses (37). For instance, both SynCAM1 and neurexin-1 are enriched in a small number of subsynaptic ensembles, but the nanoclusters of SynCAM-1 are often found near or around the border of the synapse (46, 47), whereas neurexin-1 nanoclusters tend to occur just slightly off-center within the PSD (48). How these distributions subserve particular functions is not known. LRRTM2 forms tight clusters in the PSD (37). Its enrichment within these nanoclusters in notably tighter than NL-1, which more homogenously distributes through the synapse (37), but neither the location nor function of LRRTM2 nanoclusters is known. We hypothesized that LRRTM2 may link pre- and postsynaptic nanodomains and, therefore, predicted that it is enriched with other proteins found within the transsynaptic nanocolumn (20).

To test whether LRRTM2 formed subsynaptic clusters within excitatory PSDs, we performed two-color three-dimensional (3D) dSTORM in our LRRTM2 knockdown replacement system using an anti-GFP antibody (Fig. 3A). Maps of the local density at each molecular location (Fig. 3B) showed that LRRTM2 is nonuniformly organized within the PSD, forming nanodomains of similar size and number to those previously reported for receptors and scaffolding molecules (14, 15, 37). To quantify the degree to which LRRTM2 was self-clustered, we calculated an autocorrelation measurement...
Fig. 2. No rapid loss of AMPARs following removal of the LRRTM2 extracellular domain. (A) Representative images of neuronal dendrites coexpressing GFP-Thr-LRRTM2* and PSD-95–mCherry*. The red arrow indicates the bath application of thrombin (10 U ml⁻¹). Scale bar, 10 μm. (B) Enlarged view. Scale bar, 2 μm. (C) Left: Quantification of fluorescence intensity of both GFP-Thr-LRRTM2* and PSD-95–mCherry*. Right: Summary of baseline measurements compared to 30′ after thrombin application. (n = 14 neurons/3 independent cultures). (D) Representative images of neuronal dendrites coexpressing BRS-Thr-LRRTM2* and super ecliptic pHluorin (SEP)–GluA1/2. Red arrow indicates the bath application of thrombin (10 U ml⁻¹). Scale bar, 10 μm. (E) Enlarged view. Scale bar, 2 μm. (F) Left: Quantification of fluorescence intensity of both BRS-Thr-LRRTM2* labeled with α-bungarotoxin conjugated to Alexa-647 and SEP-GluA1/2 over time normalized to their respective baseline. Right: Summary of baseline measurements compared to 30′ after thrombin application. (n = 11 neurons/3 independent cultures). (G) Representative images of immunocytochemical staining of endogenous RIM1/2 and PSD-95 from cultured hippocampal neurons expressing GFP-Thr-LRRTM2* and mCerulean3 treated with either vehicle (aCSF; top; n = 173 synapses/9 neurons/3 independent cultures) or thrombin (bottom; 10 U ml⁻¹ for 10 min; n = 176/9/3). Scale bar, 5 μm. (H) Quantification of synaptic staining intensity for PSD-95 (top) and RIM1/2 (bottom). au, arbitrary unit. (I) Cumulative distribution of synaptic staining intensities for cells treated with vehicle (aCSF; gray) or thrombin (magenta for PSD-95 and green for RIM1/2). Data are presented as means ± SEM.
and found that LRRTM2 was robustly organized into clusters with a ~100 nm diameter within synapses (Fig. 3C).

To test how LRRTM2 was organized relative to nanocolumn-resident molecules, we measured the subsynaptic organization of GFP-Thr-LRRTM2* relative to endogenous PSD-95 (Fig. 3, D and E) and RIM1/2 (Fig. 3, F and G) using an enrichment assay reported previously (20). LRRTM2 was tightly enriched within PSD-95 nanodomains (enrichment index: 1.37 ± 0.13; Fig. 3E) and aligned with RIM1/2 nanodomains across the synaptic cleft (enrichment index: 1.56 ± 0.21%; Fig. 3G). To analyze the LRRTM2 distribution with respect to that of RIM1/2 or PSD-95 without requiring the identification of nanoclusters of either protein, we measured the cross-correlation between LRRTM2 and RIM1/2 or PSD-95 density distributions (fig. S3). This demonstrated that the distributions of LRRTM2 and PSD-95 as well as LRRTM2 and RIM1/2 are highly similar to one another. To illustrate this similarity, we compared the distribution of LRRTM2 to a probe not expected to be enriched within the nanocolumn. We used an engineered single-pass transmembrane protein called SEP-TM containing an N-terminal extracellular SEP appended to the transmembrane domain from platelet-derived growth factor receptor (49). SEP-TM traffics avidly to the plasma membrane (fig. S5), but we predicted that it would not be enriched within the nanocolumn.

Fig. 3. LRRTM2 is enriched within the transsynaptic nanocolumn. (A) Schematic demonstrating the transsynaptic nanoscale organization of LRRTM2 relative to RIM and PSD-95. (B) Left: 3D dSTORM reconstruction of a dendrite from a neuron expressing GFP-LRRTM2*. Scale bar, 2 μm. Right: 3D dSTORM reconstructions of an individual synapse with localizations color coded by local density (five times nearest neighbor distance (NND)). Scale bar, 100 nm. (C) Autocorrelation of LRRTM2 synaptic clusters. (D) Schematic demonstrating the measurement of 3D coenrichment between protein pairs (LRRTM2, green; PSD-95, red). Middle (left): En face view of the localized positions of PSD-95 (red) and LRRTM2 (green) with detected nanoclusters indicated in bold. Middle (right): The same LRRTM2 localizations coded by their local density (five times NND). Scale bar, 100 nm. (E) Quantification of LRRTM2 density as a function of the distance to the PSD-95 nanocluster (NC) center. (F) LRRTM2 cross-enrichment with RIM1/2 as displayed in (D) and (E). Scale bar, 100 nm. (G) Quantification LRRTM2 cross-enrichment with RIM1/2 nanoclusters. (n = 176 nanoclusters/16 neurons/5 independent cultures). (H) Cross-enrichment of a diffuse target, SEP-TM, across from presynaptic RIM1/2 nanoclusters displayed as in (D) and (E). Scale bar, 100 nm. (n = 85/9/3). (G) Quantification of SEP-TM density as a function of the distance to the RIM1/2 nanocluster center. Data are presented as means ± SEM.
LRRTM2 is critical for AMPAR enrichment with preferential sites of evoked neurotransmitter release

Expression of LRRTM2 with mutations that disrupt its interaction with presynaptic neurexin decreases content of expressed mutant LRRTM2 at synapses and leads to lower synaptic AMPAR content and reduced AMPAR-mediated EPSCs (35, 41). However, it remains unclear whether LRRTM2 exerts ongoing control of synaptic transmission in established synapses. Given the location of LRRTM2 within the nanocolumn, we reasoned that its extracellular interactions may contribute to the nanoscale alignment of AMPARs to RIM nanodomains. To test this, we took advantage of the acute nature of the protease cleavage approach, which avoids the complications of compensation by other CAMs during the prolonged periods required for molecular expression.

Since we wanted to assure that we measured receptors only in cells where we manipulated LRRTM2 rather than near untransfected synapses, we first used two-color 3D dSTORM to measure the distribution of SEP-tagged AMPARs cotransfected with LRRTM2. Our previous work demonstrated that endogenous receptors are enriched in ~80-nm nanodomains aligned with unexpected precision to presynaptic RIM nanodomains (20). As expected, SEP-GluA1/2 AMPARs in neurons cotransfected with BRS-Thr-LRRTM2* but treated only with vehicle formed nanodomains of ~80 nm, as judged by the autocorrelation of their distributions (fig. S7, A and B). These were strongly enriched with RIM nanodomains across the cleft, decaying in enrichment over approximately 80 nm (Fig. 4A and fig. S7C).

In these neurons, we applied either vehicle [artificial cerebrospinal fluid (aCSF)] or thrombin to test the acute regulation of AMPAR organization by LRRTM2’s extracellular interactions. Brief treatment with thrombin markedly reduced the density of AMPARs directly across from RIM nanodomains (to 37.7 ± 9.1% of control enrichment index; Fig. 4A). Notably, RIM1/2 density across from detectable AMPAR nanodomains was unchanged (97.7 ± 12.2% of control; Fig. 4B), suggesting a strictly postsynaptic nanoscale reorganization of AMPAR patterning within the PSD and also that the positions of the detected AMPAR nanodomains relative to RIM1/2 nanoclusters were largely unchanged. Since we could not yet rule out that this was caused by specific or off-target effects of thrombin, we repeated the experiment except that neurons were transfected with either BRS-Thr-LRRTM2* or BRS-LRRTM2*, and both conditions received brief treatment with thrombin. Consistent with the prior result, thrombin treatment to neurons expressing the cleavable, but not the noncleavable, LRRTM2 resulted in a large reduction in AMPAR density across from RIM nanodomains (36.5 ± 27.3% of control enrichment index; Fig. 4C and fig. S7D), confirming that the effect is specific to the cleavage of the LRRTM2 ECD. Furthermore, RIM density across from these AMPAR nanodomains was again unaffected (92.5 ± 30.6% of control; Fig. 4D). To visualize this AMPAR de-enrichment another way, we calculated a 2D view of these data by aligning all receptor map data to the peak of their corresponding RIM1/2 nanocluster, producing a histogram of receptor density across from the RIM1/2 nanocluster peak averaged over all measured nanoclusters from many synapses (Fig. 4E). This output thus represents the average distribution of receptors arrayed in the synaptic membrane, facing a vesicle that might fuse at the center of a RIM nanodomain. Following thrombin treatment, the peak of this receptor array is diminished, and receptors are dispersed so that they are much less concentrated directly in line with the RIM nanodomain. Together, the rapid effect of thrombin in these experiments demonstrates that LRRTM2 via its ECD is actively involved in the nanoscale organization of AMPARs within established synapses.

Changes in either the density or arrangement of these AMPAR nanodomains could have produced changes to the enrichment measurements. To further discriminate how AMPAR organization changed upon LRRTM2 cleavage, we assayed a number of properties that these AMPAR nanoclusters exhibited. To assess the effect on RIM-AMPAR alignment without explicitly identifying nanoclusters of either protein, we measured the cross-correlation between AMPAR and RIM1/2 density distributions from the same neurons transfected with BRS-Thr-LRRTM2* or BRS-LRRTM2*. This measure showed a reduction following LRRTM2 cleavage (63.8 ± 1.3% of control; Fig. 4F), indicating that their relative density distributions became less similar, consistent with the above. Receptor nanoclusters were 67.5 ± 0.7% the volume of control receptor nanoclusters (Fig. 4G) and 28.3 ± 0.8% less numerous (Fig. 4H), while the RIM1/2 nanocluster number and volume were not altered (94 ± 10.9% and 98 ± 5.7%, respectively; Fig. 4, G and H). Furthermore, the summary enrichment data (an average of the data within 50 nm of the opposite nanocluster) demonstrated a significant decrease following LRRTM2 cleavage for AMPARs, but not RIM1/2 (Fig. 4I). Together, these data are consistent with a model of a postsynaptic nanodomain-specific de-enrichment of AMPARs near RIM nanodomains. These data provide strong evidence that, while not acutely required for controlling AMPAR number in the PSD (Fig. 2, D to F), LRRTM2’s ECD is critical for ongoing coordination of AMPAR density across from RIM nanodomains.

Numerical model to predict effects of LRRTM2 loss on synaptic transmission

These effects offer a unique opportunity to explore how changes in the nanoscale spatial organization of AMPARs in the PSD could alter receptor activation and synaptic transmission. To address this theoretically, we predicted the magnitude of the potential effect using a model based on prior work. Prior models of glutamate release and diffusion along with receptor opening kinetics have established that AMPAR open probability decreases characteristically as their distance to the site of release increases (50, 51). Beginning with this simplification enabled us to estimate the relative synaptic response after release, given different receptor distributions within the PSD without explicitly simulating glutamate diffusion or receptor kinetics.

We generated simulated receptor maps based on several key synapse features obtained from our measurements and the literature (Fig. 5, A and B, and fig. S6A). When subjected to our spatial analysis, this basal arrangement of simulated receptor positions recapitulated the autocorrelation (fig. S8B) and well reflected both the relative change in the enrichment profile (fig. S8C) and the relative change in the enrichment index (fig. S8D) for receptors as measured in our cultured neurons. To deduce how many AMPARs would need to
Fig. 4. LRRTM2 is critical for AMPAR enrichment across from preferential sites of evoked neurotransmitter release. (A) Schematic demonstrating the measurement of AMPAR localization density across from RIM1/2 nanoclusters (left). Quantification of AMPAR enrichment from neurons coexpressing BRS-Thr-LRRTM2* and SEP-GluA1/2 following treatment with thrombin (10 min; green) or vehicle (black). (B) RIM1/2 density across from AMPAR nanoclusters from neurons in (A). (C) Quantification of AMPAR enrichment from neurons coexpressing either BRS-Thr-LRRTM2* (cleavable, green; n = 95 nanoclusters/11 neurons/3 independent cultures) or BRS-LRRTM2* (noncleavable, black; n = 127/15/3) and SEP-GluA1/2 following treatment with thrombin (10 min). (D) RIM1/2 density across from AMPAR nanoclusters as displayed in (B). Quantification (cleavable, magenta; n = 90/11/3) of BRS-LRRTM2* (noncleavable, black; n = 103/15/3) and AMPARs following treatment with thrombin (10 min). (E) Representation of AMPAR density across from RIM1/2 peak density averaged across many synapses. Scale bar, 50 nm. (F) Paired cross correlation g_c(r < 50 nm) of synaptic protein pairs of SEP-GluA1/2 and RIM1/2 from thrombin-treated neurons expressing BRS-LRRTM2* (black) or BRS-Thr-LRRTM2* (green). (G) Volume of AMPAR nanoclusters. (H) Number of detected AMPAR nanoclusters. (I) Enrichment indices (g_c < 50 nm) for AMPARs across from RIM1/2 nanoclusters (gray and green, left) and RIM1/2 across from AMPAR nanoclusters (gray and magenta, right). Data are presented as means ± SEM; *P ≤ 0.05 and **P ≤ 0.01. Mann Whitney rank sum test was performed for (F) to (I).
leave the nanodomain to result in de-enrichment to the same degree as observed after cleavage of LRRTM2 (Fig. 4, F and M), we removed different number receptors from the modeled nanodomain, placed them randomly within the PSD, and then compared the enrichment profile of the redistributed synapse to that of the original modeled synapse. A loss of ~16 AMPARs from the modeled nanodomain resulted in a ~60% reduction in density within the nanodomain and well recapitulated the experimentally observed decrease in enrichment (fig. S6, C and D).

Increasing evidence suggests that evoked and spontaneous transmission involve separable presynaptic structures (52) and activate separated groups of receptors (53), but their potential differential dependence on receptor nano-organization is not known. To model the impact of receptor redistribution on these different release modes, randomized release positions were constrained either to the nanodomain or the PSD as a whole to inform our predictions about evoked and spontaneous release, respectively (Fig. 5A) (20). Then, by indexing the AMPAR peak open probability as function of distance...
from the vesicle fusion site [as in (20), shown schematically in Fig. 5C], we calculated the mean summed peak open probability of all receptors in response to single glutamate release events before and after receptor redistribution. EPSC kinetics are not captured in such a model, but the mean summed peak open probability successfully indicated that release events closer to receptor nanodomains produce larger predicted responses (Fig. 5D), consistent with results observed from Haas et al. (28).

To simulate the receptor reorganization observed after acute cleavage of LRRTM2, we removed the portion of the receptors from the nanodomain determined from the modeling above (16 of 27) and placed them randomly into the PSD outside the nanodomain. This manipulation substantially reduced the predicted response to release constrained to the receptor nanodomain (59.4 ± 0.1% of control; Fig. 5E, left). Thus, the model predicts that evoked transmission at “average” synapses would be reduced by roughly 60% after LRRTM2 cleavage. Notably, despite this strong effect, the response to release events occurring at randomized positions across the active zone was essentially unaltered (96.3% ± 0.1% of control; Fig. 5E, right). The variability of response amplitude for spontaneous release was reduced upon redistribution [coefficient of variation (CV) of 33.03% for baseline parameters and 20.31% after redistribution], suggesting that heterogeneity of receptor density across the face of an individual PSD contributes to the response CV at that synapse.

This difference between the decrement of response to release at a nanodomain or across the synapse persisted over a range of parameters. For instance, we found that, as PSD size increases, the proportional effect of receptor redistribution grows larger (Fig. 5F), suggesting that nanoalignment may be most critical for maximizing postsynaptic responsivity at large synapses. Similarly, positioning a greater fraction of receptors within the nanodomain resulted in a greater reduction in mean summed peak open probability upon redistribution (Fig. 5G), but, again, this only affected release constrained to the nanodomain, and no differences were observed in the mean of the responses with release constrained to the PSD.

A key parameter in the model is the decay profile in receptor open probability as a function of distance from the release site, here modeled by default as Po(d) = 0.42e − d/88 adapted from previous work (20, 50). To test whether the outcomes were robust to changes in this parameter, we varied this decay constant by 50% in either direction. This altered the magnitude of influence, as expected, but did not qualitatively affect the outcome. When the decay rate was decreased (−d/44), making receptors less sensitive to release position, the mean summed peak open probability after nanodomain release events was elevated as expected yet was still strongly reduced upon redistribution (Fig. 5H). Conversely, when the rate of decay was increased (−d/132), responses not only were lower but also strongly reduced after redistribution. Note that for all values of the decay constant, in response to the modeled spontaneous release events, the mean summed peak open probability was essentially unchanged by redistribution of receptors (Fig. 5H).

Together, these simulations most generally suggest that receptor distribution within a PSD strongly influences the amplitude of evoked but not average spontaneous neurotransmission at that synapse. Specifically, they predict that following LRRTM2 cleavage, the amplitude of evoked EPSCs but not spontaneous miniature EPSCs (mEPSCs) should decrease substantially.

**LRRTM2 is critical for basal strength of evoked but not spontaneous transmission**

To assess these predictions of functional effects of AMPAR nanostructural remodeling within the PSD following LRRTM2 cleavage, we performed patch-clamp recordings from cultured hippocampal neurons while stimulating nearby cells to evoke synaptic responses (Fig. 6A and fig. S9A). In untransfected neurons, thrombin application had no effect on EPSC amplitude (98.8 ± 7.7% after 10 min, n = 9; Fig. 6B), confirming a lack of nonspecific or endogenous effects of the protease. Similarly, in cells transfected with LRRTM2 knockdown and rescued with the noncleavable GFP-LRRTM2*, EPSCs were unaffected (95.5 ± 5.8%, n = 9; Fig. 6B). However, in cells transfected with GFP-Thr-LRRTM2*, acute cleavage of the LRRTM2 ECD resulted in a 45.3 ± 7.6% reduction in EPSC amplitude (n = 12; Fig. 6B), consistent with our modeling results.

Deficits in presynaptic release probability could have contributed to the decreased EPSC amplitude. To test this, we calculated the paired-pulse ratio of responses to stimuli 50 ms apart. Thrombin treatment had no effect on the paired-pulse ratio across GFP-Thr-LRRTM2*, GFP-LRRTM2*, and untransfected neurons (Fig. 6C), as well as compared to their own baselines. These data suggest that changes in release probability did not drive the changes in the evoked response amplitude after LRRTM2 cleavage.

To test the effect of LRRTM2 cleavage on the postsynaptic response to spontaneous release of glutamate, we measured mEPSCs (Fig. 6, D to I) from neurons expressing GFP-LRRTM2* or GFP-Thr-LRRTM2*. Thrombin application did not change mEPSC amplitude in cells transfected with noncleavable GFP-LRRTM2*. Neurons transfected with cleavable GFP-Thr-LRRTM2* also showed no changes to mEPSC amplitude following thrombin application (98.5 ± 3.7% of control; Fig. 6F and fig. S9B), consistent with the model’s prediction. Nevertheless, the coefficient of variation of mEPSC amplitude was smaller after thrombin exposure in neurons expressing GFP-Thr-LRRTM2* versus GFP-LRRTM2* (fig. S9G), as expected based on modeling (Fig. 5E). Together, these results suggest that the number of synaptic AMPARs was not changed upon the acute loss of the LRRTM2 ECD, consistent with results in Fig. 2 that synaptic content of both surface AMPARs and PSD-95 was unchanged within 30 min following LRRTM2 cleavage.

To further test whether loss of the LRRTM2 ECD alters presynaptic mechanisms, we quantified mEPSC frequency. Neurons transfected with the noncleavable LRRTM2 showed no changes in frequency after 10 min of thrombin exposure (91.7 ± 19.4% of control; Fig. 6G and fig. S9C), consistent with the lack of nonspecific or endogenous protease effects. Neurons transfected with GFP-Thr-LRRTM2* also showed no changes following 10 min of thrombin treatment (Fig. 6G), further strengthening the idea that the LRRTM2 ECD does not acutely regulate presynaptic release probability.

It was previously shown that extracellular cleavage of NL-1 reduced evoked EPSC amplitude without changing in mEPSC amplitude, and this was attributed to a reduction of presynaptic release probability (38). As NL-1 and LRRTM2 share presynaptic Neurexin as a ligand, we examined whether NL-1 cleavage also resulted in reorganization of transsynaptic alignment. The acute cleavage of NL-1 did not change the relative nanoalignment of RIM and AMPARs (fig. S10). This further distinguishes the unique role of LRRTM2 in maintaining synapse nanoarchitecture.

Numerical models of glutamate diffusion and AMPAR kinetics have demonstrated that glutamate release away from AMPARs...
Fig. 6. LRRTM2 is critical for basal strength of evoked but not spontaneous transmission. (A) Top: Schematic of whole-cell patch-clamp recordings from cultured hippocampal neurons with bipolar electrode stimulation to evoke synaptic currents. Bottom: Averaged traces of evoked synaptic events. Neurons transfected with GFP-Thr-LRRTM2* (light green, cleavable, post-thrombin) and GFP-LRRTM2* (dark green, noncleavable, post-thrombin), where black indicates their respective baselines. Scale bar, 100 pA, 20 ms. (B) Quantification of evoked synaptic current amplitudes normalized to their baseline measurements over time from neurons expressing GFP-LRRTM2* (dark green; n = 9 neurons/3 independent cultures), GFP-Thr-LRRTM2* (light green; n = 12/3), or untransfected neurons (gray; n = 9/3). (C) Quantification of the paired-pulse ratio. (D) Representative traces of miniature EPSC (mEPSC) recordings from cultured hippocampal neurons transfected with GFP-LRRTM2* (dark green) or GFP-Thr-LRRTM2* (light green) before and after the application of thrombin. Scale bar, 35 pA, 2 s. (E) Averaged traces of miniature synaptic currents. GFP-Thr-LRRTM2* (light green) and GFP-LRRTM2* (dark green). Scale bar, 5 pA, 2 ms. (F) Quantification of miniature synaptic current amplitudes from GFP-LRRTM2* (n = 8/3), GFP-Thr-LRRTM2* (n = 8/3), or untransfected neurons (n = 5/3) before and after the application of thrombin. (G) Quantification of miniature frequency before and after the application of thrombin. (H) Quantification of the 10 to 90% rise times of mEPSC events over time, before and after the application of thrombin. (I) Quantification of the 90 to 10% decay time of mEPSC events over time, before and after the application of thrombin. Data are presented as means ± SEM.
delays the opening of these channels by decreasing the number of immediately doubly bound receptors, leaving many in a singly bound state and slowing the rise of the EPSC as the concentration of glutamate in the cleft quickly equilibrates (54). Unfortunately, the measured variability in EPSC kinetics in our approach (which did not stimulate single presynaptic neurons for analysis) appeared to be dominated by variation in axonal conduction and other pre-synaptic factors, precluding interpretation of EPSC kinetics. However, we tested whether mEPSC kinetics were disrupted after LRRTM2 cleavage. We quantified both normalized and raw 10 to 90% rise time (Fig. 6H and fig. S9C) and 90 to 10% decay times (Fig. 6I and fig. S9D) of mEPSCs from neurons transfected with either GFP-LRRTM2* or GFP-Thr-LRRTM2* before and after the application of thrombin. Representative averaged traces (Fig. 6E) and group quantification, however, demonstrated no change in either the rise time (101.8 ± 8.9% of control; Fig. 6H) or the decay time (100 ± 4.2% of control; Fig. 6I). These results in combination with the raw and normalized miniature amplitudes (figs. S6F and S7B), which are also sensitive to changes in single-channel kinetics, suggest no population changes in AMPAR single-channel kinetics following the cleavage of the LRRTM2 ECD. These results are consistent with our numerical model of AMPAR position within the PSD (Fig. 5), where the average distance of AMPARs to the modeled spontaneous release positions across the active zone was unchanged upon AMPAR redistribution. Taking these data together, we conclude that the LRRTM2 ECD is required for close positioning of AMPARs to sites of evoked vesicle fusion and that this distribution of receptors preferentially enhances evoked but not spontaneous postsynaptic response amplitude.

**DISCUSSION**

We used acute proteolysis of the LRRTM2 ECD to test the idea that transsynaptic interactions in the synaptic cleft control molecular organization and function of established synapses, independent of synapse formation and on rapid time scales. We found that acute cleavage of LRRTM2 quickly led to dispersal of its ECD from synapses and prompted a strong reduction in the strength of evoked but not spontaneous synaptic transmission. On the basis of several lines of evidence, we conclude that this reduction in transmission arose from nanoscale redistribution of AMPARs within the synapse away from sites of glutamate release. First, LRRTM2 is concentrated in the synaptic nanocolumn, heavily enriched in nanoscale subdomains containing PSD-95 and AMPARs, and aligned transsynaptically with RIM nanodomains in the active zone. Second, after cleavage of LRRTM2, AMPARs became less densely enriched across from RIM nanodomains, although total AMPAR content in synapses as measured by immunostaining or live imaging was unchanged for at least 30 min. Third, despite marked alteration of AMPAR distribution, the acute disruption of LRRTM2 did not grossly alter synapse number, structure, or molecular content, and, notably, the total synaptic content of PSD-95 also did not change within this period of interest. Fourth, presynaptic function was unaltered, as judged by fully intact spontaneous release and evoked paired-pulse response ratio. Last, numerical modeling of AMPAR activation based on our nanostuctural measurements of AMPAR position well predicted the degree of reduction in evoked transmission while also providing a mechanism for the lack of effect on the amplitude of spontaneous EPSCs. Together, these findings provide support for a model in which the nanoscale patterning of AMPARs is dynamically controlled by interactions of LRRTM2 with cleft proteins enriched within the nanocolumn and that this organization can markedly enhance AMPAR activation during evoked synaptic transmission.

The close correspondence between our measurements and the predictions from numerical modeling provide experimental support for the longstanding notion that receptor distribution within synapses affects synaptic strength (5, 20, 55). Modeling indicates that the combination of the sharp decay of glutamate concentration away from the site of fusion with the rapid kinetics of AMPAR activation and desensitization necessitate that AMPARs positioned closest to the site of glutamate exocytosis contribute proportionally most to EPSCs (8, 50). The quick relaxation of EPSC amplitude toward a reduced steady state that we observed following LRRTM cleavage indicates that this mechanism likely plays a role in maintaining basal synaptic strength. In further support of this mechanism, sustained disruption of NL-1 also reduces alignment of AMPARs with RIM (28), suggesting that neurexin binding partners may be central to maintaining functional synaptic nanoarchitecture over multiple time scales. Mechanisms that maintain synaptic strength absent the active induction of plasticity are not clear but have been postulated to involve adhesion systems (56). Taken most broadly, our findings suggest that mechanisms of synaptic maintenance may be divided into those that establish the molecular constituent list including AMPAR number and those that facilitate appropriate nanostructural organization. It is interesting to consider whether synapses of limited molecular complexity may adopt a somewhat disorganized configuration “by default,” whereas the presence of LRRTM2 enables organization into a configuration of higher synaptic potency.

There are a number of means by which LRRTM2 may organize AMPARs. Single-cell knockout of LRRTM1 and LRRTM2 in young adult mice reduced AMPAR-mediated evoked transmission and destabilized AMPARs as measured by photoactivation without affecting synapse number, release probability, or NMDAR-mediated transmission (35, 36), suggesting that, in established synapses, LRRTMs may serve as anchors for AMPARs in the PSD. However, the role of LRRTM1 in this process appears limited, since LRRTM1 knockdown alone has no effects on evoked or spontaneous EPSC amplitudes but has substantial impact on mEPSC frequency, spine density, and synaptic vesicle distribution (57); its function may principally be limited to presynaptic roles following synaptogenesis. These findings strongly suggest that LRRTM2 plays a unique role for AMPAR retention. However, disruption of LRRTM2 did not lead to loss of AMPARs from the synapses within 30 to 60 min, although it eventually produced large changes in AMPAR stability in spines. Thus, LRRTM2 alone may not be sufficient to fulfill the functional role of “slots” hypothesized to anchor AMPARs (55, 58). Further, we cannot rule out that the transmembrane and intracellular domains of LRRTM2 that remain after thrombin cleavage may contribute to the synaptic retention of AMPARs. This would be intriguing intramolecular segregation of function within LRRTM2 for overall retention versus positioning of AMPARs. However, glycosylphosphatidylinositol–anchored LRRTM2 ECD fully rescues the deficit in long-term potentiation (LTP) during conditional deletion of LRRTM1 and LRRTM2, suggesting a specific role for the LRRTM2 ECD.

At the subsynaptic scale, the patterned distribution of AMPARs is generally thought to be stabilized by a combination of factors despite continuous receptor diffusion in the plasma membrane (15, 59, 60): a heterogenous affinity landscape in the synapse created by the distribution of direct AMPAR binding partners (61) and an array of...
s teric obstacles that creates macromolecular crowding and hinders their motion within the dense synaptic environment (49, 62). We suspect that both these mechanisms may be involved in how LRRTM2 controls the AMPAR pattern. There is some evidence that the LRRTM2 ECD can interact directly with AMPARs (33, 36) [but see (63)] and that LRRTM2 through its interaction with PSD-95 might dynamically organize intracellular scaffolds (32, 33). At the same time, its loss may trigger reorganization or even loss of synapse-resident proteins that could alter the steric hindrance experienced by receptors in the cleft by their large ECDs or in the substantially denser PSD by their smaller intracellular domains. In addition, partitioning of the PSD via liquid-liquid phase separation is being actively investigated as a potential organizing mechanism of synaptic nanostructures (64). Because of multivalent interactions facilitated by LRRTM2 in the synaptic cleft, its presence could serve to establish a nanoscale, phase-separated synaptic subdomain into which AMPARs partition and which would be disturbed by the cleavage of the LRRTM2 ECD (although we do not know of evidence that LRRTM2 is cleaved endogenously). Overall, regardless of the mechanism, our data indicate that the nanoscale organization of AMPARs is both modulated by the LRRTM2 ECD and capable of rapid reorganization.

These observations are particularly interesting given that strong evidence also implicates LRRTM2 in LTP (36). Conditional deletion of LRRTM1 and LRRTM2 in mature mice reduces LTP in vivo, and expression of the LRRTM2 ECD alone, but not LRRTM4, is sufficient to rescue these deficits (35), clearly consistent with our observation that acute loss of the ECD regulates synaptic strength. Similarly, point mutations to the LRRTM2 ECD that disrupt presynaptic neurexin binding fail to completely rescue LTP (35), suggesting that neurexin binding may help explain how LRRTM2 specifically organizes AMPARs with respect to active zone nanodomains. LRRTM2 has been proposed as an anchor that stabilizes AMPARs during LTP induction (35, 36). Our work extends this by implying that synaptic nanostructure shaped by LRRTM2 may play several roles in functional plasticity. Most simply, LRRTM2-augmented AMPAR activation may lower the threshold of activity needed to trigger plasticity. Existing LRRTM2 nanodomains could also facilitate the stabilization of recently exocytosed or otherwise labile receptors (3). Similarly, it is conceivable that LRRTM2 could nucleate new nanoclusters added during LTP (65, 66), although activity-dependent trafficking of LRRTM2 remains uninvestigated. In addition, our prior observation that chemical LTP induction “sharpens” the AMPAR distribution under RIM nanodomains (20) may suggest further that graded levels of AMPAR organizational tuning could be facilitated by LRRTM2. Most broadly, it is a natural extension of our findings here to suggest that behavioral or disease-relevant plasticity mechanisms, even regardless of the potential involvement of LRRTM2, may regulate synaptic strength not only by regulating AMPAR number but also through controlling synapse nanoarchitecture.

Unexpectedly, we found that the average postsynaptic response to spontaneous release was rather insensitive to AMPAR nanoorganization, although it remains to be seen whether this holds for all synapse geometries (e.g., small synapses). Our model and others predict that different forms of release may produce different postsynaptic responses depending on the subsynaptic distribution of release sites. There is indeed evidence that mEPSCs and univisceral EPSCs evoked in the presence of Sr2+ differ in CV and amplitude from action potential-evoked EPSCs in the same neurons (67, 68), and our findings provide novel experimental support for the idea. However, one shortcoming in previous work and our own is that, because of the large variation in synaptic potency even on single neurons, precise measures of both mEPSCs and evoked quantal size from the same synapses (not merely the same cells) will be needed for thorough experimental validation of these predictions. Such differences may be important because while the roles of spontaneous synaptic transmission remain unclear, it has been suggested to stabilize the basal structure and function of the postsynapse (52, 69, 70). Local activity driven by spontaneous neurotransmitter release is also important for restricting the lateral mobility of AMPARs, helping to trap them in the PSD (71). Implicating transcellular mechanisms in the distinct regulation of evoked and spontaneous transmission further distinguishes these two forms of transmission already known to operate with heterogeneity at different active zones (72).

The effects of disrupting LRRTM2 and NL-1 differ in several ways, both electrophysiologically and molecularly. Perhaps most markedly, our experiments showed that acute manipulation of LRRTM2, but not NL-1, quickly prompted disorganization of AMPARs, whereas, in similar experiments, proteolytic cleavage of NL-1 rapidly altered synaptic neurexin content and reduced presynaptic release probability (38). Thus, even adhesion molecules that share binding partners may play unexpectedly divergent roles in maintaining organization of synaptic molecular complexes. More broadly, these results suggest that many specific aspects of synapse structure and function are maintained by unique subsets of the diverse cell adhesion systems present within single synaptic clefts. Growing evidence demonstrates that synaptic CAMs themselves are found in distinct subsynaptic patterns (5, 37, 46, 48). Clearer understanding of CAM organization within synapses will provide insight into their contribution to synapse nanooarchitecture and to their cooperative or even competitive functional roles.

MATERIALS AND METHODS

Plasmids

All LRRTM2 plasmids were generated on the basis of FCK-shLRRTM2 and pBOS-GFP-hLRRTM2-FL described previously (33). For insertion of the thrombin cleavage site, the sequence coding the four Ser’s (S386 to S389) was replaced with a sequence coding the cleavage site (LVPGRS) with a flexible linker (GGGGs) on each side. For knockdown rescue experiments in neurons, the H1 promoter and sh-LRRTM2 sequences from FCK-shLRRTM2 were subcloned into the pBOS-GFP-hLRRTM2-FL around the Mlu I site with in vivo assembly (IVA) cloning (73). For BRS-LRRTM2, GFP sequence was replaced with a sequence coding the α-bungarotoxin–binding sequence (WRYYESSLEPPD) (44). GFP-NL-1 and GFP-NL-1-Thr were gifts from M. Ehlers (38).

Coculture synaptogenesis assay

Coculture assays were performed as described (74). Briefly, neurons were dissociated from embryonic day 18 (E18) Sprague-Dawley (SD) rat hippocampi, plated at a density of 60,000 cells on 12-mm cover glasses precoated with poly-l-lysine (1 mg/ml) (Sigma-Aldrich, P1274), and treated at 2 days in vitro (div) for 24 hours with Ara-C (2 μM) to prevent gliial growth. Neurons were cultured in Neurobasal medium (Invitrogen, 21103-049) with 3% B27 (Invitrogen, 17504-001) and 1% GlutaMAX (Invitrogen, 35050-061) and incu-
Transfected HEK293 cells were suspended 24 hours later and seeded onto 8 div neurons at a density of 5000 HEK cells per 12-mm cover glass. Ara-C was added at 2 μM upon seeding to prevent HEK cell overgrowth. After 48 hours, cocultures were fixed on 10 div with 4% paraformaldehyde (PFA) and 4% sucrose in phosphate-buffered saline (PBS), stained with primary antibodies diluted in 3% fetal bovine serum (FBS) and 0.01% Triton X-100 (TX-100) in PBS, and incubated overnight at 4°C. Secondary antibodies were diluted in 3% PBS and applied for 4 hours at 4°C. Neuronal cultures were stained with mouse monoclonal antibodies against Bassoon (1:500; Assay Designs, catalog no. VAM–PS003F, RRID: AB_2313991) and α-bungarotoxin–Alexa-647. Secondary immunostaining was performed with Alexa dye–conjugated antibodies. Coverslips were mounted with Aqua-PolyMount (Thermo Fisher Scientific, NC9439247). Confocal microscopy was performed on a Leica TCS SP8. Images were acquired with an ACS APO 63× oil lens with a 1.3 numerical aperture (NA) using the same settings for each condition. During image acquisition and analysis, the researcher was blind to the condition. Images were analyzed using a custom-written ImageJ script available upon request.

**Hippocampal culture and transfections**

All experimental protocols were approved by the University of Maryland School of Medicine Institutional Animal Care and Use Committee or the Institutional Animal Care and Use Committees at the University of Science and Technology of China and the Chinese Academy of Sciences. Dissociated hippocampal neurons from E18 SD rats of both sexes were prepared as described previously (76). Neurons were transfected on 7 to 10 div with Lipofectamine 2000, and experiments were performed at least 7 days after the transfection (14 to 21 div). All experiments were repeated on three or more separate cultures unless otherwise specified.

**Immunocytochemistry**

Neurons were fixed in 4% PFA and 4% sucrose in PBS for 10 min at room temperature and processed for immunofluorescence with standard procedures as described previously (20). Primary antibodies were rabbit anti-RIM1/2 (1:500; Synaptic Systems, no.140203), mouse anti–PSD-95 (1:200; NeuroMab, clone K28/43), and chicken anti-GFP (1:200; Chemicon, ab13970). Secondary antibodies were from the Jackson ImmunoResearch (West Grove, PA), either already conjugated with Alexa-647 or unconjugated that we labeled with Cy3b (GE Healthcare). Labeling with the anti-GFP antibody was performed after fixation but before overt permeabilization.

Live-cell BRS labeling with α-bungarotoxin conjugated to Alexa-647 was performed before fixation described above. Coverslips were inverted on 50-μl droplets of α-bungarotoxin–Alexa-647 (1:100; Thermo Fisher Scientific, B35450) in aCSF containing 2 mM Ca2+ and 2 mM Mg2+ and covered for 5 min at room temperature (21° to 24°C). Then, coverslips would be placed into a small weighing boat filled with aCSF and gently agitated, removing and replacing the aCSF twice before mounting in the microscope imaging chamber.

For LRRTM2 and PSD-95 immunocytochemistry, neurons were fixed in 2% PFA and 4% sucrose in cytoskeleton buffer [10 mM MES (pH 6.8), 138 mM KCl, 3 mM MgCl2, 2 mM EGTA, and 320 mM sucrose] for 8 min at room temperature. Coverslips were then washed three times for 5 min each with PBS/glycine (Gly). Cells were permeabilized with 0.3% TX-100 in PBS/Gly for 20 min at room temperature and then washed once in PBS/Gly with 0.1% TX-100 for 5 min. Blocking was performed with a solution containing 3% bovine serum albumin, 5% goat serum, 5% donkey serum, and 0.1% TX-100 for 1 hour and 15 min. Coverslips were inverted and incubated with primary antibodies [LRRTM2, immunoglobulin 1A (IgG1A) mouse, NeuroMab N209C/35.3, 1:10; αPSD-95, IgG2A, 1:80; stored in 50% glycerol] diluted in a 1:1 dilution of the blocking media and PBS/Gly overnight in a humidity chamber at 4°C. Coverslips were then washed three times in PBS/Gly containing 0.1% TX-100 for 5 min. Secondaries (GoM IgG1A Alexa-647, 1:200; the Jackson laboratory, 115-605-205, lot 143997; DzeM IgG2A, 1:200; the Jackson laboratory, catalog 20257, lot 14C0225) were diluted in a 1:1 dilution of the blocking media, and PBS/Gly and coverslips were inverted on secondary in a humidity chamber at room temperature for 1 hour. Then, coverslips were washed three times with PBS/Gly for 5 min. Cells were postfixed with 4% PFA and 4% sucrose in PBS for 15 min and then washed three times with PBS/Gly for 5 min.

All imaging except for dSTORM and HEK coculture assay was performed on an Andor Dragonfly spinning disk confocal on either an Olympus IX81 or a Nikon Ti2 microscope. In each case, a 60×/1.45 NA oil immersion objective and Zyla scientific complementary metal-oxide semiconductor (sCMOS) camera were used, with an image format of 103 nm per pixel. Except where indicated, experiments were conducted at room temperature (22° to 24°C). Otherwise, for imaging in culture medium, a stage-top incubator and objective heater (Tokai Hit) maintained the sample temperature at 37°C and CO2 at 5%.

**Proteolytic cleavage**

Thrombin from bovine plasma (Sigma-Aldrich, T4648-1KU, lot # SLBV3604) was diluted in the imaging buffer (aCSF; 2 mM Ca2+ and 2 mM Mg2+) at 100 U/ml such that, when added to the bath by pipette, the final concentration became 10 U/ml. Thrombin was added dropwise away from the objective into the media containing cells in the imaging chamber at 24°C. Thrombin was stored at −20°C with a volume of at least 600 μl and only underwent one freeze-thaw cycle. For imaging at 0.003 Hz, cells were maintained at 24°C. Z-stacks were taken every 5 min, and a maximum intensity projection was used for analysis. For imaging at 20 Hz, cells were kept on the objective at 24°C. Imaging was performed with 488-nm excitation during continuous acquisition at 20 Hz. Binning (2 × 2) permitted the identification of modestly expressing synaptic puncta at lowest possible laser power to prevent photobleaching. Exposure was 50 ms per frame. Data were smoothed with a sliding average window with a bin length of three frames (150 ms). For all experiments, chamber was thoroughly washed with deionized water and 70% ethanol accompanied by physical scrubbing to completely remove residual thrombin that can adhere to the plastics and rubber of the imaging chamber and O ring. All synaptic region of interest (ROI) measurements were background subtracted and normalized to an average of each synapse's own baseline.

**Quantification of protein retention at synapses Live (30 min)**

Cells were cotransfected with GFP-Thr–LRRTM2* or BRS-Thr–LRRTM2* and PSD-95–mCherry* or SEP-GluA1,2, respectively. For PSD-95 experiments, multiposition z-stacks were acquired every 5 min. For analysis, maximum intensity projections were calculated. ROIs of a fixed size (15 pixels) were drawn around synaptic puncta containing both LRRTM2 and PSD-95–mCherry* or SEP-GluA1/2 fluorescence.
Integrated intensity was measured, background subtracted (an average of multiple ROIs across the field of view), and then normalized to an average of the ROIs’ pre-thrombin baseline. Only spines that remained within the ROI for the duration of imaging were included. 

**Live (2 hours)**

Cells were cotransfected with SEP-GluA1,2 and BRS-LRRTM2* or BRS-Thr-LRRTM2*. Multiposition z-stacks were taken every 15 or 20 min. For analysis, maximum intensity projections were calculated. ROIs of a fixed size (25 pixels) were drawn around synaptic puncta containing both LRRTM2 and SEP-GluA1,2 fluorescence. Integrated intensity was measured, background subtracted (an average of multiple ROIs across the field of view), and then normalized to an average of the ROIs’ pre-thrombin baseline. Only spines that remained within the ROI for the duration of imaging were included.

**Fixed**

Cells were cotransfected with GFP-Thr-LRRTM2* and mCerulean3. Cells were immunostained for PSD-95 and RIM1/2 as described above. All regions were acquired with the same imaging parameters on the Dragonfly confocal. For analysis, background subtracted (values taken from an average of multiple background regions across the field) integrated intensity within an ROI of a fixed size (15 pixels). Values were additionally normalized to the median intensity in the field that helped to normalize potential differences in any region-to-region variability in staining intensity. Normalization to median intensity did not appear to be skewed by artifactual puncta, as these were avoided during acquisition or occupied a very small fraction of total pixels in the field.

**24-hour post-thrombin**

Cells were cotransfected with SEP-GluA1,2 and BRS-LRRTM2* or BRS-Thr-LRRTM2*. Both groups were treated with thrombin for 10 min and then returned to culture media. Then, 24 hours later, cells were fixed and stained for GFP and the BRS-tagged LRRTM2 ECD as described above. All regions were acquired with the same imaging parameters on the Dragonfly confocal scanning disk (Andor). For analysis, maximum intensity projections were calculated. ROIs of a fixed size (15 pixels) were drawn around GFP puncta. Integrated intensity was measured and routinely background subtracted (an average of multiple ROIs across the field of view).

**Quantification of PSD-95 puncta density**

Cells were transfected with cytosolic mCerulean3 alone or paired with either pBOS-shLRRTM2 [tgcttctactcgactcde (33)], GFP-Thr-LRRTM2* (this paper), or pBOS-GFP-Thr-LRRTM2 (this paper). Cells were then fixed and immunostained for PSD-95 (described above), mCerulean fluorescence was used to demarcate the dendrites of transfected cells. Using mCerulean fluorescence alone to remain blinded to the transfection condition, up to the first six transfected cells were selected for imaging and further analysis to reduce bias. Regions were chosen at least ~75 µm from the soma when dealing with a clear primary dendrite to avoid volume effects. Distance was calculated by drawing a line in ImageJ (total pixel number × pixel size). All images were thresholded the same. Each punctum had to consist of at least four suprathreshold pixels. Experimenter was blind to the condition during image analysis.

**Quantification of spine morphology**

Cells (4 to 6 div) were transfected with mCerulean3 alone or mCerulean3 paired with GFP-Thr-LRRTM2*. Cells were imaged at 14 to 16 div. Maximum intensity projections of the confocal stacks were analyzed in ImageJ by an observer blinded to conditions. Analysis between groups was always performed within the same culture. For spine length, a line was drawn from the edge of the spine head to the edge of the dendrite, parallel to the long axis of the spine (total pixel number × pixel size). For spine area, an ROI was drawn around the spine head. The images were thresholded on the basis of intensity, and the area was measured in ImageJ. The experimenter was blind to the condition during image analysis.

**Colocalization analysis**

Cells were transfected with GFP-Thr-LRRTM2*. Synapses were picked on the basis of colocalization with dendritic spines. Five consecutive spine-resident, GFP-positive puncta were selected randomly from at least four separate dendritic regions per cell when possible. When few branches were present, selection of dendritic ROIs was as evenly distributed throughout the image as possible. The data represent the number of those randomly selected GFP-positive puncta that also contained at least four suprathreshold pixels of PSD-95 or RIM1/2 staining. Analysis was performed using ImageJ. The experimenter was blind during data analysis.

**3D STORM imaging**

Imaging was performed essentially as described (20) on an Olympus IX81 ZDC2 inverted microscope with a 100×/1.49 total internal reflection fluorescence (TIRF) oil immersion objective. Excitation light was reflected to the sample via a 405/488/561/638 quadband polychroic (Chroma) with an incident angle near but less than the critical angle. The typical incident power out of objective was ~30 mW for 647 nm and ~60 mW for 561 nm. Emission was passed through an adaptive optics device (MicAO, Imagine Optic), which corrected the aberrations and introduced astigmatism for 3D imaging. A Photometrics DV2 was inserted before an iXon+ 897 electron multiplying charge-coupled device camera (Andor) for simultaneous collection of the red and far-red emissions. All hardware was controlled via iQ software (Andor), except the MicAO, which was controlled via Micromanaker. Z stability was maintained by the Olympus ZDC2 feedback positioning system. Imaging of NL-1 experiments was carried out on a Nikon ECLIPSE Ti2 inverted microscope equipped with a perfect focusing system and an 100×/1.49 TIRF oil immersion objective controlled with NIS-Elements AR 4.30.02 software; emission was collected with a CMOS camera (ORCA-Flash4.0, Hamamatsu); localization detection, calibration, and drift correction were done using the NIS-Elements AR analysis 4.40.00 software. Lateral drift was corrected with a cross-correlation drift correction approach (24). Samples were imaged in a STORM imaging buffer freshly made before experiments containing 50 mM tris, 10 mM NaCl, 1% glucose, glucose oxidase (0.5 mg/ml; Sigma-Aldrich), catalase (40 µg/ml; Sigma-Aldrich), and 0.1 M cysteamine (Sigma-Aldrich). TetraSpeck beads (100 nm; Invitrogen) immobilized within a thin layer of 4% agarose on a coverslip were localized across a z-stack with 30-nm steps to get the 3D calibration and correct alignment between the two channels as described previously. The average deviation of the bead localizations after correction was <15 nm in x/y directions and 40 to 50 nm in z.

**Single-molecule localization and analysis of synaptic clusters**

All data analysis was performed offline using custom routines in MATLAB (MathWorks). The lateral (x and y) and axial (z) coordinates of single fluorophores were determined from the centroid...
position and ellipticity of the fitted elliptical 2D Gaussian function to a $7 \times 7$ pixel array (pixel size of 160 nm) surrounding the peak. Poorly localized peaks were removed with a set of rejection criteria including an $x$-$y$ precision < 10 nm, fitting $R^2 > 0.6$, and comprising >200 photons, as well as the shape of peaks (24). For peaks lasting for more than one frame, only the localizations in the first frame were included in further analysis.

Synapses were identified as a juxtaposed pair of localization clusters of synaptic proteins, and only those with clear pre- and postsynaptic components were selected for further analysis. A DB-SCAN filter was applied to the selected synaptic localizations with the MATLAB function “DBSCAN.m” created by S. M. K. Heris to define the boundaries of synaptic clusters. Only those localizations with a minimum of 60 localizations (MinPts = 60) within a radius of five times the mean nearest neighboring distance (MNND) ($\varepsilon = 5 \times$ MNND $\approx 100-120$ nm) were considered within the synaptic cluster. The cluster boundaries were defined by an $\alpha$ shape with $\alpha = 150$ nm.

### Nanocluster detection and protein enrichment analysis

Nanoclusters within synaptic clusters were automatically identified on the basis of local densities defined as the number of localizations within a certain distance ($d$) from each localization. To account for the variation in localization density across different synaptic clusters, we defined $d$ as $2.5 \times$ MNND instead of a fixed value (77). The threshold of local density for nanocluster detection was defined as Mean(LD0) + 4 × Std(LD0), where LD0 is the local density of a randomized cluster with the same overall density as the synaptic cluster. The threshold we used represented the 99.95% confidence interval that the measured density differs from chance.

All localizations above the threshold were then ranked on the basis of their local densities in a descending order and assigned each localization sequentially as the peak of a new nanocluster or a part of an existing nanocluster based on whether it was further enough from peaks of all existing nanoclusters. The localization with highest local density, if above the threshold, was defined as the peak of the first nanocluster. The second-highest density localization would be considered as the peak of another potential nanocluster if the distance between the first peak to this potential second peak was larger than the defined cutoff distance; otherwise, the second localization was considered a part of the first nanocluster. The minimum peak-to-peak distance was set as 80 nm, which is about the average size of synaptic nanoclusters (15, 20, 78). Then, each potential nanocluster was further divided into subclusters based on the point-to-point distance with a cutoff of $2 \times$ MNND using the MATLAB function “clustera,” and only the subcluster having the original peak localization of this potential nanocluster was selected. Last, the subclusters had to include at least four localizations to be accepted as a nanocluster.

The enrichment analysis is based on the prediction that, if the pre- and postsynaptic nanoclusters align across the cleft, the presence of a nanocluster on one side will predict a higher local protein density around its projected point on the other side. The synaptic cluster pair was first translated to overlap with each other based on their general shape without bias toward local densities (20, 77). The enrichment was then quantified as the average local density of protein A over the distance from the projected peak of a protein B nanocluster. In case of a positive alignment, this curve would start from a local density significantly higher than the average at a small distance and then decay to the average. More details and the defined MATLAB function for nanocluster detection and protein enrichment analysis could be found in (77). The experimenter was blind during image analysis.

### Automatic en face projection and averaging of synapses

A plane parallel to the cleft was defined by fitting all localizations after the translation (least square of the normal distance to the plane). The 2D en face projection was achieved with calculation of the projected coordinates of all localizations along the fitted plane. To avoid the potential dilution of local density after the collapse of 1D, maximal projection of 3D local density was made to generate the density map of projected cluster. To visualize the en face distribution of both RIM1/2 and PSD-95 around PSD-95 nanoclusters, we averaged both normalized density maps centered on the projected peaks of PSD-95 nanoclusters. Meanwhile, to avoid any artifact created by the bordering effect, all values outside the synaptic cluster were replaced with 1 before averaging was performed (77).

### Numerical model to estimate peak open probability of AMPARs

We used a constrained deterministic approach to test how different AMPAR organizations could affect the peak open probability of AMPARs at individual synapses based on key biological measurements. The calculation of $\sum \text{[peak open probability]}$, also denoted as $\sum \text{[peak p(o)]}$, is adapted from previous stochastic modeling (20, 50), where the probability of channel opening characteristicly decays as a function of the distance to the position of glutamate exocytosis. This relationship has been modeled here as $P(\text{p}) = 0.42e^{-r/88}$, as described previously (20).

AMPAR positions were randomly generated in MATLAB using cirrdnPJ.m, which creates points within a circle of a specified size, essentially building a map of randomized AMPAR positions with 2D coordinates. We considered this the modeled PSD area, and this area was determined by values taken from prior electron microscopy work (79). The number of points to be generated within the PSD area was taken from prior work (80). Using a separate loop of cirrdnPJ.m, another smaller radius could be specified within the larger PSD area in which points were randomly generated. We considered this the modeled nanodomain, and it contained the average number of AMPARs suggested to form these nanodomains (78).

These modeled AMPAR organizations containing a single nanodomain were examined using our spatial analysis. The autocorrelation measurement, as described previously (20) for both biological and modeled localization data, was used to measure the size of these modeled subsynaptic clusters. The detected size of the modeled nanodomain was similar to the subsynaptic organizations observed in the biological data where the profile decays back to 1 at $\sim 80$ nm, indicating the size of the modeled nanodomain. Of course, AMPAR nanodomains found in biological synapses can range in number affecting the amplitude of this measurement due to the increased frequency of the signal, and multiple nanodomains in one synapse will show a larger amplitude when measured by the autocorrelation. Since we only model a single nanodomain within the synapse, the autocorrelation correctly demonstrates a lower amplitude than the measured biological data.

These modeled AMPAR organizations were examined using our enrichment analysis (20, 77). This analysis measures the density of points as a function of distance beginning at a specified position and moving out radially at determined step sizes (distance in nanometers). Using the previously described baseline parameters, and in agreement
with the autocorrelation, the enrichment analysis successfully demonstrated that these modeled AMPAR positions show subsynaptic enrichment decaying to the average synaptic density by ~80 nm, and this measure was expectedly sensitive to the number of AMPARs included in the nanodomain. Then, the sensitivity of the threshold-based nanocluster detection algorithm, which can detect the number of points included in a subsynaptic cluster, was adjusted until it successfully indicated that, on average, ~27 AMPARs were in nanodomain.

To reflect the redistribution of AMPARs within synapses observed in the biological data by dSTORM, some number of AMPARs had to be removed from the nanodomain, but not lost from the PSD (Figs. 2 and 6), which is referred to here as “redistribution.” The specific mechanisms driving AMPAR position after this redistribution remain unclear, for instance, whether AMPARs are specifically excluded following LRRTM2 cleavage have not been determined. To reflect this in our model, AMPARs were simply placed back randomly into the modeled PSD, thus not specifically excluded from the nanodomain area after redistribution. Then, using the enrichment profile and enrichment index as readouts of this reorganization, AMPARs were redistributed using this approach until the modeled enrichment index and modeled enrichment profile closely approximated the difference in the measured enrichment index and measured enrichment profile of AMPARs in biological synapses compared to their respective controls. Then, using the nanocluster detection algorithm adjusted to detect the modeled “ground truth” number of AMPARs previously, we redistributed AMPARs and quantified how many AMPARs were still considered to be “in nanodomain” after redistribution. Some nanodomains were no longer detectable given the magnitude of reorganization, which is consistent with our observations in Fig. 4I.

The open probability of AMPARs is thought to critically depend on the distance to the site of glutamate exocytosis. Release position has been thought to occur in spatially distinct subregions of the active zone given different modes of neurotransmitter release, thus influencing this key parameter. To understand how different constraints on release position in the active zone affect AMPAR open probability, we modeled two modes of release, again using cirrdnPf.m to randomize AMPAR positions within a specified area. Release constrained to the nanodomain is referred to here as “evoked release,” as it is thought to occur over a smaller fraction of the PSD and aligned with postsynaptic AMPAR nanodomains. We refer to release over the entire area of the PSD as “spontaneous release,” as it does not demonstrate a similar constraint in release position distribution determined by live imaging of vesicle fusion events (20).

Then, using the baseline parameters as a starting point and our modeled redistribution of AMPARs given the data from Fig. 4 (F and M) (as described above), we calculated the open probability of each AMPAR in the modeled PSD. This was done by indexing the distance of each AMPAR to the modeled vesicle release position. Then, by summing these probabilities across every AMPAR in the modeled PSD, we could estimate the number of AMPARs on average that would generally be expected to open in response to spontaneous or evoked release. This informed the interpretations of the electrophysiology from neurons that underwent LRRTM2 cleavage and subsequent AMPAR redistribution. To test how these various spatial parameters (“PSD area,” “proportion of AMPARs in the nanodomain,” and the “decay constant of the decay profile”) used in the model influenced AMPAR open probability, we kept the baseline parameters constant except for the parameter being tested and repeated the redistribution of AMPAR positions described above over a reasonable biological range.

**Electrophysiology**

Whole-cell recordings were made on neurons from 13 to 17 div with 5- to 8-megohm pipettes filled with an internal solution that contained the following: 130 mM CsMeSO₃, 6 mM NaCl, 10 mM Hepes, 1 mM MgCl₂, 2 mM Na₂-bis(2-aminophenoxo)ethane-N,N,N’,N”-tetraacetic acid–K, 0.2 mM CaCl₂, 3 mM Mg–adenosine triphosphate (ATP), and 0.3 mM tris–guanosine triphosphate (GTP) (pH 7.3) with CsOH (290 to 295 mOsM). Neurons were held at ~70 mV at which the GABAergic current was minimal. The bath solution consisted of the following: 130 mM NaCl, 2.5 mM KCl, 1 mM Na₂PO₄, 10 mM Hepes, X mM CaCl₂, 4-X mM MgSO₄, and 10 mM glucose. Lower [Ca²⁺]₀ (X = 0.5–1) was used for evoked EPSC recordings to reduce the recurrent activity, while for mEPSC recordings, normal [Ca²⁺]₀ (X = 2) combined with tetrodotoxin (1 μM) and picrotoxin (50 μM) was used. Evoked EPSCs were elicited by 1 ms extracellular field stimuli through a bipolar electrode made from 9-shape glass pipette with an opening of 2 to 3 μm. The stimulation electrode was held a few micrometers above the cells and moved around to locate at a position where single-peak, monosynaptic currents were reliably evoked. The paired stimuli with a 50 ms interval were delivered every 10 s. For mEPSCs, glass pipettes were pulled to have a resistance of 3 to 6 meegohm. An internal solution containing 130 mM K-gluconate, 5 mM KCl, 2 mM MgCl₂, H₂O, 10 mM Hepes, 4 mM Mg-ATP, 0.3 mM Na₂-GTP, 10 mM Na₂-phosphocreatine, and 1 mM EGTA was used to record at room temperature (21° to 24°C). The series resistances were monitored, and data with changes of >20% were discarded. The capacitance and input resistance were not significantly different between different groups of neurons. Data were collected with MultiClamp 700B amplifiers (Molecular Devices) and digitized at 5 kHz with Digidata 1440 and Clampex 10 software (Molecular Devices). mEPSCs were detected by fitting to a variable amplitude template using pClamp 10 analysis software. The experimenter was blinded to condition during data analysis.

**Statistical analysis**

We used two-tailed Student’s t or Mann-Whitney rank sum tests for comparisons between two groups. We used a one-way analysis of variance (ANOVA) with post hoc Dunnett’s test for multiple comparisons of three groups. Data are presented as means ± SEM except otherwise noted. Significance levels are displayed as follows: n.s., not significant, P > 0.05; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. These tests were performed in Prism 8.2.0 (GraphPad).

**SUPPLEMENTARY MATERIALS**

Supplementary material for this article is available at https://advances.sciencemag.org/cgi/content/full/7/34/eabf3126/DC1

**REFERENCES AND NOTES**

1. R. Malinow, R. C. Malenka, AMPA receptor trafficking and synaptic plasticity. *Annu. Rev. Neurosci.* **25**, 103–126 (2002).
2. M. Sheng, M. J. Kim, Postsynaptic signaling and plasticity mechanisms. *Science* **298**, 776–780 (2002).
3. R. L. Huganir, R. A. Nicoll, AMPARs and synaptic plasticity: The last 25 years. *Neuron* **80**, 704–717 (2013).
D. Freche, U. Pannasch, N. Rouach, D. Holcman, Synapse geometry and receptor dynamics modulate synaptic strength. PLOS ONE 6, e25122 (2011).

P. M. Burger, E. Melh, P. L. Cameron, P. R. Maycox, M. Baumert, F. Lottspeich, P. De Camilli, R. Jahn, Synaptic vesicles that are isolated from rat cerebral cortex contain high levels of glutamate. Neuron 3, 715–720 (1989).

J. D. Clements, R. A. J. Lester, G. Tong, C. E. Jahr, L. Gary, J. A. D. Clements, R. A. J. Lester, G. Tong, C. E. Jahr, G. L. Westbrook, The time course of glutamate in the synaptic cleft. Science 258, 1498–1501 (1992).

C. Tang, M. Dichter, M. Morad, Quisqualate activates a rapidly inactivating high affinity glutamate receptor. Neuron 12, 361–621 (2002).

J. D. Clements, R. A. J. Lester, G. Tong, C. E. Jahr, L. Gary, J. A. D. Clements, R. A. J. Lester, G. Tong, C. E. Jahr, G. L. Westbrook, The time course of glutamate in the synaptic cleft. Science 258, 1498–1501 (1992).

Y. Fukuta, A. Dimitrov, G. Boncompain, O. Vielemeyer, F. Perez, M. Fukata, Local palmitoylation cycles define activity-regulated postsynaptic subdomains. J. Cell Biol. 202, 145–161 (2013).

S. M. Airaksinen, S. M. Strattmater, A. M. Craig, Deletion of LRRTM1 and LRRTM2 in adult mice impairs basal AMPA receptor transmission and LTP in hippocampal CA1 pyramidal neurons. Proc. Natl. Acad. Sci. U.S.A. 115, E5382–E5389 (2018).

J. Ko, M. V. Fuccillo, R. C. Malenka, T. C. Südhof, LRRTM2 functions as a neurexin ligand in promoting excitatory synapse formation. Neuron 64, 791–798 (2009).

D. Choquet, A. Triller, The dynamic synapse. Curr. Opin. Neurobiol. 21, 267–268 (2011).

H. Chen, A. H. Tang, T. A. Blanpied, Transsynaptic spatial organization as a regulator of postsynaptic glutamate receptors. J. Neurosci. 33, 843–856 (2010).

J. A. DeGiorgi, J. A. Galbraith, A. Dosemeci, X. Chen, T. S. Reese, Distribution of the scaffolding proteins PSD-95, PSD-93, and SAP97 in isolated PSDs. Brain Cell Biol. 35, 239–250 (2006).

T. C. Südhof, The presynaptic active zone. Neuron 75, 11–25 (2012).

J. B. Sibthia, S. Park, M. Sainlos, O. Thoumine, Mapping the dynamics and nanoscale organization of synaptic adhesion proteins using monoclonal streptavidin. Nat. Commun. 7, 10773 (2016).

R. T. Peixoto, P. A. Kunz, H. Kwon, A. M. Mabb, L. B. Sabatini, B. D. Phlipot, M. D. Ehlers, Transsynaptic signaling by activity-dependent cleavage of neurelin-1. Neuron 76, 396–409 (2012).

J. Gottmann, D. Goel, M. Jusyte, D. Laber, A trans-synaptic nanocolumn aligns neurotransmitter release to receptors. Neuron 56, 680–696 (2017).

D. Comoletti, P. Taylor, A. Ghosh, LRRTM2 interacts with neurexin1 and regulates excitatory synapse formation. Neuron 64, 799–806 (2009).

Y. Sekine-Aizawa, R. L. Huganir, Imaging of receptor trafficking by using α-bungarotoxin-binding-site-tagged receptors. Proc. Natl. Acad. Sci. U.S.A. 101, 17114–17119 (2004).

D. Choquet, A. Triller, The dynamic synapse. Neuron 80, 691–703 (2013).

K. Perez de Arce, N. Schrod, S. W. R. Metzbower, E. Allgeyer, G. K. W. Kong, A. H. Tang, A. J. Krupp, V. Stein, X. Liu, J. Bewersdorff, T. A. Blanpied, V. Lucici, T. Biederer, Topographic mapping of the synaptic cleft into adhesive nanodomains. Neuron 88, 1165–1172 (2015).

M. A. Böhme, A. W. McCarthy, A. T. Grasskamp, C. B. Beuschel, P. Goel, M. Jusyte, D. Laber, S. Huang, U. Pannasch, R. A. J. Lester, G. Tong, C. E. Jahr, G. L. Westbrook, The time course of glutamate in the synaptic cleft. Science 258, 1498–1501 (1992).
58. P. Opazo, M. Sainlos, D. Choquet, Regulation of AMPA receptor surface diffusion by PSD-95 slots. Curr. Opin. Neurobiol. 22, 453–460 (2012).
59. M. C. Ashby, S. R. Maier, A. Nishimune, J. M. Henley, Lateral diffusion drives constitutive exchange of AMPA receptors at dendritic spines and is regulated by spine morphology. J. Neurosci. 26, 7046–7055 (2006).
60. L. Groc, D. Choquet, Linking glutamate receptor movements and synapse function. Science 368, eaa4631 (2020).
61. J. García-Nafria, B. Herguedas, J. F. Watson, I. H. Greger, The dynamic AMPA receptor extracellular region: A platform for synaptic protein interactions. J. Physiol. 594, 5449–5458 (2016).
62. M. Renner, P. N. Lacor, P. T. Velasco, J. Xu, A. Contractor, W. L. Klein, A. Triller, Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGlur5. Neuron 66, 739–754 (2010).
63. J. Schwenk, N. Harmel, A. Brechet, G. Zolles, H. Berkefeld, C. S. Müller, W. Bildl, D. Baehrens, B. Hüber, A. Kulik, N. Klöcker, U. Schulte, B. Fakler, High-resolution proteomics unravel architecture and molecular diversity of native AMPA receptor complexes. Neuron 74, 621–633 (2012).
64. X. Wu, Q. Cai, Z. Feng, M. Zhang, Liquid-liquid phase separation in neuronal development and synaptic signaling. Dev. Cell 55, 18–29 (2020).
65. M. Hruska, N. Henderson, S. J. Le Marchand, H. Jafri, M. B. Dalva, Synaptic nanomodules underlie the organization and plasticity of spine synapses. Nat. Neurosci. 21, 671–682 (2018).
66. J. Lisman, Glutamatergic synapses are structurally and biochemically complex because of multiple plasticity processes: Long-term potentiation, long-term depression, short-term potentiation and scaling. Philos. Trans. R. Soc. B Biol. Sci. 372, 20160260 (2017).
67. J. M. Bekkers, J. D. Clements, Quantal amplitude and quantal variance of strontium-induced asynchronous EPSCs in rat dentate granule neurons. J. Physiol. 516, 227–248 (1999).
68. V. Y. Bolshakov, S. A. Siegelbaum, Regulation of hippocampal transmitter release during development and long-term potentiation. Science 269, 1730–1734 (1995).
69. M. A. Sutton, H. T. Ito, P. Cressy, J. C. Kempf, Miniature synaptic events maintain dendritic spines via AMPA receptor activation. Nat. Neurosci. 2, 44–49 (1999).
70. M. D. Ehlers, M. Heine, L. Groc, M. C. Lee, D. Choquet, Diffusional trapping of GluR1 AMPA receptors by input-specific synaptic activity. Neuron 54, 447–460 (2007).
71. P. Schieffele, Mixed-culture assays for analyzing neuronal synapse formation. Nat. Protoc. 2, 670–676 (2007).
72. J. Biedrer, P. Schieffele, Electrically isolated and cultured hippocampal neurons as a useful tool to study AMPA receptor function and trafficking. J. Physiol. 564, 489–501 (2005).
73. J. García-Nafria, J. F. Watson, I. H. Greger, IVA cloning: A single-tube universal cloning system exploiting bacterial in vivo assembly. Sci. Rep. 6, 27459 (2016).
74. T. Biedrer, P. Schieffele, Mixed-culture assays for analyzing neuronal synapse formation. Nat. Protoc. 2, 670–676 (2007).
75. Y. Fukumoto, Y. Obata, K. Ishibashi, N. Tamura, I. Kikuchi, K. Aoyama, Y. Hattori, K. Tsuda, Y. Nakayama, Y. Yamaguchi, Cost-effective gene transfection by DNA compaction at pH 4.0 using acidified, long shelf-life polyethyleneimine. Cytotechnology 62, 73–82 (2010).
76. N. A. Frost, H. Shroff, H. Kong, E. Betzig, T. A. Blanpied, Single-molecule discrimination of discrete perisynaptic and distributed sites of actin filament assembly within dendritic spines. Neuron 67, 86–99 (2010).
77. J. H. Chen, T. A. Blanpied, A. H. Tang, Quantification of trans-synaptic protein alignment: A data analysis test case for single-molecule localization microscopy. Methods 174, 72–80 (2020).
78. D. Nair, E. Hsy, J. D. Petersen, A. Constals, G. Giannone, D. Choquet, J.-B. Sibarita, Super-resolution imaging reveals that AMPA receptors inside synapses are dynamically organized in nanodomains regulated by PSD95. J. Neurosci. 33, 13204–13224 (2013).
79. K. M. Harris, J. K. Stevens, Dendritic spines of CA1 pyramidal cells in the rat hippocampus: Serial electron microscopy with reference to their biophysical characteristics. J. Neurosci. 9, 2982–2997 (1989).
80. M. Matsuzaki, G. C. R. Ellis-Davies, T. Nemoto, Y. Miyashita, M. Iino, H. Kasai, Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat. Neurosci. 4, 1086–1092 (2001).

Acknowledgments: We thank M. Contreras for assistance and preparation of cell cultures and members of the Blanpied laboratory for comments and help on experiments, analysis, and this manuscript. Funding: This work was supported by the National Institute of Mental Health F31MH116583 (to A.M.R.), the Brain and Behavior Research Foundation NARSAD Young Investigator Award and National Natural Science Foundation of China 31872759 (to A.-H.T.), the National Institute of Mental Health R01MH086828 (to S.M.T.), the National Institute on Drug Abuse R01DA018928 (to T.B.), the National Institute of Mental Health R01MH119826 (to T.A.B. and T.B.), and the National Institute of Mental Health R37MH080046 (to T.A.B.). Author contributions: A.-H.T., A.M.R., T.A.L., and T.A.B. designed the experiments. A.M.R., A.-H.T., T.A.L., X.-Z.G., and B.E.C. conducted the experiments and data analysis. A.-H.T., A.M.R., T.B., and T.A.B. performed and analyzed the coculture experiments. A.M.R. drafted the original manuscript. A.M.R., A.-H.T., and T.A.B. wrote the performed electrophysiology experiments. B.E.C. and T.B. performed and analyzed the coculture experiments. All authors contributed to editing the manuscript and evaluating the data. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Submitted 19 October 2020
Accepted 30 June 2021
Published 20 August 2021
10.1126/sciadv.abf3126

Citation: A. M. Ramsey, A.-H. Tang, T. A. LeGates, X.-Z. Gou, B. E. Carbone, S. M. Thompson, T. Biedrer, T. A. Blanpied, Subsynaptic positioning of AMPARs by LRRTM2 controls synaptic strength. Sci. Adv. 7, eabf3126 (2021).
Subsynaptic positioning of AMPARs by LRRTM2 controls synaptic strength
Austin M. Ramsey, Ai-Hui Tang, Tara A. LeGates, Xu-Zhuo Gou, Beatrice E. Carbone, Scott M. Thompson, Thomas Biederer, and Thomas A. Blanpied

Sci. Adv., 7 (34), eabf3126.
DOI: 10.1126/sciadv.abf3126

View the article online
https://www.science.org/doi/10.1126/sciadv.abf3126
Permissions
https://www.science.org/help/reprints-and-permissions